In vitro proton magnetic resonance spectroscopy of liver tissue informs in vivo hepatic proton magnetic resonance spectroscopy studies
Jeremy F.L. Cobbold, Simon D. Taylor‐Robinson, I. Jane Cox – 28 August 2008
Reply:
Joel G. Fletcher, Luis S. Guimaraes, Jeff L. Fidler, Patrick S. Kamath – 28 August 2008
Of mice and molecular mimicry: Modeling autoimmune hepatitis
David G. Bowen – 28 August 2008
The extent of vacuolation in non–heart‐beating porcine donor liver grafts prior to transplantation predicts their viability
Diethard Monbaliu, Louis Libbrecht, Rita De Vos, Katrien Vekemans, Hugo Walter, Qiang Liu, Veerle Heedfeld, Vera Goossens, Jacques Pirenne, Tania Roskams – 28 August 2008 – Livers exposed to prolonged warm ischemia (WI), such as those from non–heart‐beating donors (NHBDs), are at higher risk of primary graft nonfunction (PNF). In a pig model of liver transplantation (LTx) from NHBDs, hepatocellular vacuolation, focal hepatocyte dropout, congestion, and sinusoidal dilatation appeared on biopsies taken after exposure to WI.
Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal
Jeffrey Campsen, Michael A. Zimmerman, James F. Trotter, Michael Wachs, Thomas Bak, Tracy Steinberg, Maria Kaplan, Franklin Wright, Igal Kam – 28 August 2008 – Our center has attempted to minimize corticosteroid (CS) use in all of our orthotopic liver transplantation (OLT) recipients. Because patients with autoimmune hepatitis (AIH) typically require CSs after transplantation, we reviewed our experience in this cohort of patients to determine (1) patient outcomes including recurrent disease and (2) long‐term requirements for CS use in AIH patients.
Biliary tract complications: The most common postoperative complication in living liver donors
James D. Perkins – 28 August 2008
Assessment and management of psychosocial challenges in pediatric liver transplantation
Eyal Shemesh – 28 August 2008
Reply:
Muhammad Y. Sheikh – 28 August 2008
Spontaneous hepatitis B surface antigen seroclearance confers appreciably high rates except in patients with relapse of hepatitis
Yong‐Ning Xin, Shi‐Ying Xuan – 28 August 2008
Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis
Sebastian Klammt, Steffen R. Mitzner, Jan Stange, Jan Loock, Uwe Heemann, Jörg Emmrich, Emil C. Reisinger, Reinhard Schmidt – 28 August 2008 – Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n = 12; control: n = 10) during a period of 30 days in a randomized controlled clinical ECAD trial.